Tandem Diabetes Care, Inc. is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4). Its technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism, which draws insulin from a flexible bag within the pump's cartridge rather than relying on a syringe and plunger mechanism. It also features a software, which is a vivid color touch screen and a micro- universal serial bus (USB) connection that supports both a rechargeable battery and uploads to t:connect Diabetes Management Application (t:connect), its custom cloud-based data management application that provides display therapy management data from the pump and supported blood glucose meters.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Symbol: NASDAQ:TNDM
- CUSIP: N/A
- Web: www.tandemdiabetes.com
Capitalization:- Market Cap: $30.3 million
- Outstanding Shares: 50,228,000
Average Prices:- 50 Day Moving Avg: $0.62
- 200 Day Moving Avg: $0.92
- 52 Week Range: $0.39 - $8.81
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.56
- P/E Growth: -0.01000
Sales & Book Value:- Annual Revenue: $81.51 million
- Price / Sales: 0.35
- Book Value: ($0.36) per share
- Price / Book: -1.57
Profitability:- EBIDTA: ($76,170,000.00)
- Net Margins: -110.70%
- Return on Equity: -1,177.11%
- Return on Assets: -87.18%
Debt:- Debt-to-Equity Ratio: -4.09%
- Current Ratio: 2.11%
- Quick Ratio: 1.28%
Misc:- Average Volume: 1.30 million shs.
- Beta: 0.36
- Short Ratio: 3.34
Frequently Asked Questions for Tandem Diabetes Care (NASDAQ:TNDM)
What is Tandem Diabetes Care's stock symbol?
Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."
How were Tandem Diabetes Care's earnings last quarter?
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) released its quarterly earnings results on Thursday, July, 27th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.04. The company earned $21.30 million during the quarter, compared to analysts' expectations of $21.74 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 110.70%. The firm's revenue was down 7.4% compared to the same quarter last year. During the same period last year, the business posted ($0.60) earnings per share. View Tandem Diabetes Care's Earnings History.
When will Tandem Diabetes Care make its next earnings announcement?
Where is Tandem Diabetes Care's stock going? Where will Tandem Diabetes Care's stock price be in 2017?
9 brokers have issued 1-year price targets for Tandem Diabetes Care's stock. Their predictions range from $1.50 to $11.00. On average, they expect Tandem Diabetes Care's share price to reach $5.08 in the next twelve months. View Analyst Ratings for Tandem Diabetes Care.
Are investors shorting Tandem Diabetes Care?
Tandem Diabetes Care saw a increase in short interest during the month of August. As of August 15th, there was short interest totalling 2,305,655 shares, an increase of 41.1% from the July 31st total of 1,634,155 shares. Based on an average trading volume of 715,813 shares, the days-to-cover ratio is presently 3.2 days. Approximately 6.3% of the company's shares are sold short.
Who are some of Tandem Diabetes Care's key competitors?
Some companies that are related to Tandem Diabetes Care include Bioquell plc (BQE), Capnia (SLNO), Surgical Innovations Group Plc (SUN), Alliqua BioMedical (ALQA), Lombard Medical (EVAR), Cytori Therapeutics (CYTX), NeuroMetrix (NURO), InspireMD (NSPR), CareFusion (CFN), Covidien Ltd (COV), CRH Medical Corp (CRHM), CRH Medical Corp (CRHM), CRH Medical Corp (CRHM), Great Basin Scientific (GBSN), LDR Holding Corp (LDRH) and Syneron Medical (ELOS).
Who are Tandem Diabetes Care's key executives?
Tandem Diabetes Care's management team includes the folowing people:
- Dick P. Allen, Chairman of the Board
- Kim D. Blickenstaff, President, Chief Executive Officer, Board Member
- John Cajigas, Chief Financial Officer, Treasurer
- John F. Sheridan, Chief Operating Officer, Executive Vice President
- Brian Hansen, Chief Commercial Officer, Executive Vice President
- Susan M. Morrison, Chief Administrative Officer
- Lori Gildea, Vice President - Sales
- David B. Berger Esq., General Counsel, Corporate Secretary
- Edward L. Cahill, Independent Director
- Fred E. Cohen Ph.D. M.D., Independent Director
Who owns Tandem Diabetes Care stock?
Tandem Diabetes Care's stock is owned by many different of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (9.76%), Wasatch Advisors Inc. (6.32%), TPG Group Holdings SBS Advisors Inc. (4.97%), Vanguard Group Inc. (2.46%), DAFNA Capital Management LLC (1.44%) and Russell Investments Group Ltd. (1.17%). Company insiders that own Tandem Diabetes Care stock include Dick Allen, John F Sheridan and Kim D Blickenstaff. View Institutional Ownership Trends for Tandem Diabetes Care.
Who sold Tandem Diabetes Care stock? Who is selling Tandem Diabetes Care stock?
Who bought Tandem Diabetes Care stock? Who is buying Tandem Diabetes Care stock?
Tandem Diabetes Care's stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Keybank National Association OH, Vanguard Group Inc., Frontier Capital Management Co. LLC and Falcon Point Capital LLC. Company insiders that have bought Tandem Diabetes Care stock in the last two years include Dick Allen and Kim D Blickenstaff. View Insider Buying and Selling for Tandem Diabetes Care.
How do I buy Tandem Diabetes Care stock?
Shares of Tandem Diabetes Care can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tandem Diabetes Care's stock price today?
One share of Tandem Diabetes Care stock can currently be purchased for approximately $0.57.
MarketBeat Community Rating for Tandem Diabetes Care (NASDAQ TNDM)MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Tandem Diabetes Care (NASDAQ:TNDM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.44) |
| Consensus Price Target: | $5.08 (791.66% upside) |
Analysts' Ratings History for Tandem Diabetes Care (NASDAQ:TNDM)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/3/2017 | B. Riley | Reiterated Rating | Neutral | $1.50 | Medium |  |
| 4/10/2017 | Cowen and Company | Downgrade | Outperform -> Market Perform | $1.50 | Medium | |
| 3/30/2017 | Wedbush | Reiterated Rating | Outperform | $11.00 | Low | |
| 3/30/2017 | Piper Jaffray Companies | Reiterated Rating | Neutral -> Neutral | | Medium | |
| 3/9/2017 | Northcoast Research | Reiterated Rating | Buy | | N/A | |
| 11/2/2016 | Deutsche Bank AG | Lower Price Target | Buy | $14.00 -> $9.00 | N/A | |
| 11/2/2016 | Feltl & Co. | Downgrade | Strong-Buy -> Buy | | N/A | |
| 11/2/2016 | Robert W. Baird | Downgrade | Outperform -> Neutral | $11.00 -> $4.00 | N/A | |
| 11/2/2016 | Stifel Nicolaus | Downgrade | Buy -> Hold | $15.00 -> $3.50 | N/A | |
| 5/16/2016 | Sterne Agee CRT | Reiterated Rating | Neutral | | N/A | |
| 3/24/2016 | Bank of America Corporation | Downgrade | Neutral -> Underperform | | N/A | |
| 10/21/2015 | William Blair | Reiterated Rating | Market Perform | | N/A | |
(Data available from 9/20/2015 forward)
Earnings History for Tandem Diabetes Care (NASDAQ:TNDM)Earnings History by Quarter for Tandem Diabetes Care (NASDAQ TNDM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/30/2017 | | ($0.44) | | | | | N/A | |
| 7/27/2017 | Q2 2017 | ($0.48) | ($0.44) | $21.74 million | $21.30 million | View | N/A | |
| 4/27/2017 | Q1 2017 | ($0.66) | ($0.75) | $15.72 million | $17.50 million | View | N/A | |
| 3/8/2017 | Q4 2016 | ($0.65) | ($0.48) | $22.75 million | $24.80 million | View | Listen | |
| 7/28/2016 | Q216 | ($0.65) | ($0.60) | $23.08 million | $23.00 million | View | Listen | |
| 4/28/2016 | Q116 | ($0.69) | ($0.68) | $17.67 million | $20.06 million | View | N/A | |
| 2/24/2016 | Q415 | ($0.51) | ($0.40) | $29.17 million | $29.10 million | View | Listen | |
| 10/29/2015 | Q3 | ($0.80) | ($0.65) | $12.58 million | $15.70 million | View | Listen | |
| 7/30/2015 | Q215 | ($0.71) | ($0.65) | $14.92 million | $15.70 million | View | Listen | |
| 4/30/2015 | Q115 | ($0.79) | ($0.83) | $12.19 million | $12.30 million | View | N/A | |
| 2/24/2015 | Q414 | ($0.81) | ($0.78) | $17.16 million | $17.90 million | View | N/A | |
| 11/6/2014 | Q314 | ($0.82) | ($0.85) | $13.60 million | $13.50 million | View | N/A | |
| 7/31/2014 | Q214 | ($0.91) | ($0.83) | $10.36 million | $10.26 million | View | N/A | |
| 5/6/2014 | Q1 | ($0.69) | ($0.96) | $8.24 million | $8.10 million | View | N/A | |
| 11/8/2011 | | $0.25 | $0.18 | | | View | N/A | |
| 8/9/2011 | | $0.26 | $0.20 | | | View | N/A | |
| 5/10/2011 | | $0.24 | $0.24 | | | View | N/A | |
| 3/14/2011 | | $0.29 | $0.18 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Tandem Diabetes Care (NASDAQ:TNDM)2017 EPS Consensus Estimate: ($1.79)
2018 EPS Consensus Estimate: ($1.17)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | ($0.81) | ($0.62) | ($0.71) |
| Q2 2017 | 4 | ($0.63) | ($0.37) | ($0.46) |
| Q3 2017 | 4 | ($0.50) | ($0.33) | ($0.38) |
| Q4 2017 | 5 | ($0.28) | ($0.21) | ($0.25) |
| Q1 2018 | 2 | ($0.34) | ($0.34) | ($0.34) |
| Q2 2018 | 2 | ($0.34) | ($0.28) | ($0.31) |
| Q3 2018 | 2 | ($0.28) | ($0.28) | ($0.28) |
| Q4 2018 | 2 | ($0.28) | ($0.20) | ($0.24) |
(Data provided by Zacks Investment Research)
Dividend History for Tandem Diabetes Care (NASDAQ:TNDM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tandem Diabetes Care (NASDAQ:TNDM)Insider Ownership Percentage: 20.90%
Institutional Ownership Percentage: 36.64%
Insider Trades by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/23/2017 | Kim D Blickenstaff | CEO | Buy | 1,600,000 | $1.25 | $2,000,000.00 | |
| 8/1/2016 | John F Sheridan | EVP | Sell | 15,000 | $6.52 | $97,800.00 | |
| 5/2/2016 | John F Sheridan | COO | Sell | 2,000 | $10.61 | $21,220.00 | |
| 4/22/2016 | John F Sheridan | COO | Sell | 2,000 | $10.00 | $20,000.00 | |
| 3/7/2016 | John F Sheridan | COO | Sell | 4,000 | $10.01 | $40,040.00 | |
| 2/26/2016 | Dick Allen | Director | Buy | 10,000 | $8.24 | $82,400.00 | |
| 12/1/2015 | John F. Sheridan | COO | Sell | 2,000 | $10.14 | $20,280.00 | |
| 11/2/2015 | John F. Sheridan | COO | Sell | 4,000 | $10.00 | $40,000.00 | |
| 9/14/2015 | John F. Sheridan | COO | Sell | 2,000 | $12.51 | $25,020.00 | |
| 5/1/2015 | John F Sheridan | COO | Sell | 2,000 | $13.72 | $27,440.00 | |
| 4/1/2015 | John F Sheridan | COO | Sell | 2,000 | $12.47 | $24,940.00 | |
| 2/2/2015 | John F Sheridan | COO | Sell | 2,000 | $12.06 | $24,120.00 | |
| 1/2/2015 | John F Sheridan | COO | Sell | 2,000 | $12.75 | $25,500.00 | |
| 12/12/2014 | Dick Allen | Director | Buy | 10,000 | $11.95 | $119,500.00 | |
| 12/1/2014 | John F Sheridan | COO | Sell | 2,000 | $13.55 | $27,100.00 | |
| 11/3/2014 | John F Sheridan | COO | Sell | 2,000 | $16.00 | $32,000.00 | |
| 10/1/2014 | John F Sheridan | COO | Sell | 2,000 | $13.07 | $26,140.00 | |
| 9/2/2014 | John F Sheridan | COO | Sell | 2,000 | $13.99 | $27,980.00 | |
| 8/1/2014 | John F Sheridan | COO | Sell | 2,000 | $15.04 | $30,080.00 | |
| 7/1/2014 | John F Sheridan | COO | Sell | 2,000 | $16.42 | $32,840.00 | |
| 6/18/2014 | John F Sheridan | COO | Sell | 2,000 | $16.75 | $33,500.00 | |
| 11/13/2013 | David B Berger | General Counsel | Buy | 2,000 | $15.00 | $30,000.00 | |
| 11/13/2013 | Hlm Venture Partners Ii, L.P. | Major Shareholder | Buy | 200,000 | $15.00 | $3,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Tandem Diabetes Care (NASDAQ:TNDM)
Latest Headlines for Tandem Diabetes Care (NASDAQ:TNDM)
| Source: |
|
| Date | Headline |
|---|
 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tandem Diabetes Care, Inc.
finance.yahoo.com - September 8 at 9:20 AM |
 | Tandem Diabetes Care, Inc. (TNDM) Expected to Post Quarterly Sales of $26.07 Million
www.americanbankingnews.com - September 6 at 1:28 PM |
| Tandem Diabetes Care, Inc. (TNDM) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 5 at 8:54 AM |
| ETFs with exposure to Tandem Diabetes Care, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 9:55 AM |
 | BRIEF-Tandem Diabetes Care announces FDA approval, launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration
www.reuters.com - August 30 at 10:17 AM |
| Tandem Diabetes Care Announces FDA Approval and Launch of t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM Integration
finance.yahoo.com - August 29 at 8:47 AM |
| Today's Research Reports on Trending Tickers: Gilead Sciences Inc. and Tandem Diabetes Care Inc.
finance.yahoo.com - August 29 at 8:46 AM |
| Tandem Diabetes Care, Inc. (TNDM) Short Interest Update
www.americanbankingnews.com - August 28 at 1:20 AM |
 | Tandem Diabetes (TNDM) Granted Patent for Remote Bolus Feature on Medical Infusion Pumps
www.streetinsider.com - August 25 at 1:13 AM |
 | Tandem Diabetes awarded new U.S. patent covering insulin pump; shares ahead 4% after hours
seekingalpha.com - August 24 at 8:11 PM |
| Tandem Diabetes Care Announces Issuance of Patent Related to Remote Bolus Feature for Medical Infusion Pumps
finance.yahoo.com - August 24 at 8:11 PM |
| Tandem Diabetes Care Announces Launch of t:lock Connector for its Insulin Pump Cartridges and Infusion Sets
finance.yahoo.com - August 23 at 12:39 PM |
| Critical Contrast: Exactech (EXAC) and Tandem Diabetes Care (TNDM)
www.americanbankingnews.com - August 21 at 2:24 PM |
| Tandem Diabetes Care, Inc. (TNDM) Expected to Post Quarterly Sales of $26.16 Million
www.americanbankingnews.com - August 18 at 9:42 AM |
| Tandem Diabetes Care Inc (TNDM) Expected to Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - August 16 at 4:32 PM |
| Tandem Diabetes Care Begins Enrollment in Pivotal Trial for First Touchscreen Insulin Pump with Predictive Low Glucose Suspend (PLGS)
finance.yahoo.com - August 16 at 8:17 AM |
| Invacare Corporation (IVC) versus Tandem Diabetes Care (TNDM) Financial Review
www.americanbankingnews.com - August 15 at 11:10 AM |
| ETFs with exposure to Tandem Diabetes Care, Inc. : August 14, 2017
finance.yahoo.com - August 15 at 7:46 AM |
| Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 5:06 PM |
| Tandem Diabetes nabs U.S. patent related to portable infusion pump safety features; shares ahead 2%
seekingalpha.com - August 9 at 8:17 AM |
| Tandem Diabetes Care Announces Issuance of Patent Related to Important Safety Features for Portable Infusion Pumps that Utilize Touchscreen Control
finance.yahoo.com - August 9 at 8:17 AM |
| Tandem Diabetes Care, Inc. (TNDM) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 2 at 8:32 AM |
 | Medical Supplies Stock Performance Review -- Tandem Diabetes Care, Merit ...
www.prnewswire.com - August 2 at 7:54 AM |
 | Tandem Diabetes Care to Present at the 2017 Wedbush PacGrow Healthcare Conference
www.businesswire.com - August 2 at 7:54 AM |
| Tandem Diabetes Care, Inc. :TNDM-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017
finance.yahoo.com - August 1 at 6:58 AM |
| $26.59 Million in Sales Expected for Tandem Diabetes Care, Inc. (NASDAQ:TNDM) This Quarter
www.americanbankingnews.com - July 31 at 9:33 AM |
| Analysts Expect Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Will Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - July 29 at 10:08 AM |
| Edited Transcript of TNDM earnings conference call or presentation 27-Jul-17 8:30pm GMT
finance.yahoo.com - July 29 at 7:58 AM |
| Tandem Diabetes Care's (TNDM) CEO Kim Blickenstaff on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - July 28 at 8:52 AM |
| Tandem Diabetes Care Reports Second Quarter 2017 Financial Results
finance.yahoo.com - July 28 at 8:52 AM |
| Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Announces Earnings Results
www.americanbankingnews.com - July 27 at 9:08 PM |
| Tandem Diabetes Care, Inc. (TNDM) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 19 at 8:52 AM |
| Tandem Diabetes Care, Inc. (TNDM) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 17 at 10:54 AM |
| Tandem Diabetes Care, Inc. (TNDM) Short Interest Down 35.3% in June
www.americanbankingnews.com - July 17 at 7:24 AM |
| Tandem Diabetes Care Schedules Second Quarter 2017 Earnings Press Release and Conference Call
finance.yahoo.com - July 14 at 9:18 AM |
| ETFs with exposure to Tandem Diabetes Care, Inc. : July 13, 2017
finance.yahoo.com - July 14 at 9:18 AM |
| Zacks: Analysts Anticipate Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Will Announce Quarterly Sales of $21.83 Million
www.americanbankingnews.com - July 7 at 2:42 PM |
| Tandem Diabetes Care, Inc. (TNDM) Expected to Post Earnings of -$0.48 Per Share
www.americanbankingnews.com - July 5 at 9:50 AM |
| Tandem Diabetes Care, Inc. (TNDM) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - June 20 at 8:34 AM |
| Tandem Diabetes Care Presents Findings from Predictive Low Glucose Suspend (PLGS) Feasibility Study and Announces Approval of Investigational Device Exemption (IDE) for Pivotal Trial
finance.yahoo.com - June 12 at 7:43 PM |
| $21.83 Million in Sales Expected for Tandem Diabetes Care Inc (TNDM) This Quarter
www.americanbankingnews.com - June 11 at 10:02 AM |
| Analysts Expect Tandem Diabetes Care Inc (TNDM) to Announce -$0.49 EPS
www.americanbankingnews.com - June 9 at 7:40 AM |
| Tandem Diabetes Care Inc (TNDM) Short Interest Up 14.4% in May
www.americanbankingnews.com - June 5 at 8:40 AM |
| ETFs with exposure to Tandem Diabetes Care, Inc. : June 2, 2017
finance.yahoo.com - June 2 at 3:28 PM |
| Tandem Diabetes Care Inc (TNDM) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 26 at 8:51 AM |
| ETFs with exposure to Tandem Diabetes Care, Inc. : May 19, 2017
finance.yahoo.com - May 19 at 6:14 PM |
| Tandem Diabetes Care Inc (TNDM) Expected to Announce Quarterly Sales of $21.83 Million
www.americanbankingnews.com - May 14 at 8:45 AM |
| -$0.49 EPS Expected for Tandem Diabetes Care Inc (TNDM) This Quarter
www.americanbankingnews.com - May 13 at 12:04 AM |
| ETFs with exposure to Tandem Diabetes Care, Inc. : May 8, 2017
finance.yahoo.com - May 8 at 7:45 PM |
| Somewhat Positive Media Coverage Somewhat Likely to Impact Tandem Diabetes Care (TNDM) Stock Price
www.americanbankingnews.com - May 3 at 8:36 PM |
Tandem Diabetes Care (TNDM) Chart for Wednesday, September, 20, 2017
